DiaMedica
- Company typePublic
- Founded2000
- HeadquartersMinneapolis, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
DiaMedica firmographics
Firmographics- Name
- DiaMedica
- Legal name
- DiaMedica Therapeutics, Inc.
- Website
- https://diamedica.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
DiaMedica industry classification
Industry- Product category
- Clinical-Stage Biopharmaceuticals (Ischemic/Vascular Therapeutics)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)
- akta.pro secondary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where DiaMedica is headquartered
LocationHeadquarters
- HQ city
- Minneapolis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
DiaMedica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development / Licensing Revenue: DiaMedica is a pre-revenue clinical-stage biopharmaceutical company. All revenue potential is contingent on successful clinical development, regulatory approval, and commercialization of DM199. The company may pursue licensing agreements or co-development partnerships for commercialization. As of the available data, the company has no approved products and generates no product revenue.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
DiaMedica product offering
Product offeringCore offering
DiaMedica is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1), as a novel therapeutic for three ischemic/vascular indications: preeclampsia (Phase 2), fetal growth restriction (Phase 2), and acute ischemic stroke via the Phase 2/3 ReMEDy2 trial. The drug acts through the kallikrein-kinin system to restore vascular health, reduce inflammation and oxidative stress, and is currently advancing in clinical trials with no approved products or product revenue.
Product overview
DiaMedica is a clinical-stage biopharmaceutical company developing a single lead drug candidate, DM199 (rinvecalinase alfa), which is a recombinant form of human tissue kallikrein-1 (KLK1) protein. The company is advancing DM199 through multiple clinical programs including: (1) the Phase 2/3 ReMEDy2 trial for acute ischemic stroke, (2) Phase 2 trials for preeclampsia, and (3) Phase 2 trials for fetal growth restriction. The drug candidate works by restoring vascular health and function through vasodilation and reducing inflammation and oxidative stress.
Differentiator
Problem solved
Functional benefit
Products and services
- DM199 (rinvecalinase alfa) for Acute Ischemic Stroke — ReMEDy2 Phase 2/3 Trial Recombinant human tissue kallikrein-1 (rhKLK1) protein administered to acute ischemic stroke patients who are not candidates for tPA or mechanical thrombectomy, with the goal of enhancing collateral blood flow to reduce ischemic injury. Being studied in the Phase 2/3 ReMEDy2 trial at ~70 activated sites across the U.S., Canada, U.K., and Europe.
- DM199 (rinvecalinase alfa) for Preeclampsia — Phase 2 Trial Subcutaneous DM199 (rinvecalinase alfa) being evaluated in a Phase 2 open-label, dose-ranging trial for early-onset preeclampsia in pregnant women between 24 and 32 weeks gestation, with the goal of stabilizing blood pressure and reducing uterine artery resistance without crossing the placental barrier.
- DM199 (rinvecalinase alfa) for Fetal Growth Restriction — Phase 2 Trial Subcutaneous DM199 (rinvecalinase alfa) under evaluation in a Phase 2 trial in pregnant women with early-onset fetal growth restriction (27–32 weeks gestation), targeting up to 30 patients with the goal of improving placental blood flow and fetal growth outcomes.
Quantifiable outcome
- 25 mmHg systolic and 13 mmHg diastolic blood pressure reduction in preeclampsia proof-of-concept study; 13% statistically significant reduction in uterine artery resistance index
- +3 more outcomes
Companies that use DiaMedica
Customer profileSegments3 records
Ideal customer profiles3 records
DiaMedica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
DiaMedica partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor.
- Jefferies Global Healthcare ConferenceminorDiaMedica presented at the Jefferies Global Healthcare Conference in June 2026 (New York), conducting fireside chats and company presentations. The company participates in multiple healthcare investor conferences for investor engagement and capital markets visibility.
- TD Cowen Annual Healthcare ConferenceminorDiaMedica participated in TD Cowen's 46th Annual Healthcare Conference in Boston (March 2026) for investor relations and visibility among institutional investors and analysts.
- Barclays Global Healthcare ConferenceminorDiaMedica participated in Barclays' 28th Annual Global Healthcare Conference in Miami (March 2026) for investor engagement and company presentations.
- Leerink Partners Global Healthcare ConferenceminorDiaMedica participated in Leerink Partners' Global Healthcare Conference in Miami (March 2026) for fireside chats and one-on-one meetings with investors.
- RedChip Biotech Investor ConferenceminorCEO Rick Pauls presented at the RedChip Biotech Investor Conference (April 2026), highlighting clinical data for DM199 in preeclampsia and acute ischemic stroke programs, and discussing upcoming stroke trial interim analysis catalyst.
Scale indicators14 records
Recent moves6 records
Expansion highlights5 records
DiaMedica competitors and assessment
Company assessmentDirect peers
- NoNO Inc. Privately-held clinical-stage biotech developing nerinetide (NA-1), a neuroprotectant for acute ischemic stroke. Directly comparable to DM199 as a non-thrombolytic biologic targeting the same large unmet need of stroke patients ineligible for tPA/thrombectomy.
- Athersys: Clinical-stage biotech developing MultiStem cell therapy for ischemic stroke (MASTERS-2 trial). Closely comparable to DiaMedica as a small-cap clinical-stage stroke biotech with multi-asset pipeline and similar capital constraints.
- ReNeuron Group: Clinical-stage cell therapy company developing CTX stem cell therapy for stroke disability. Comparable as a small-cap, clinical-stage biotech pursuing novel biologic mechanisms for ischemic stroke.
- ZZ Biotech: Clinical-stage biotech developing 3K3A-APC, a recombinant protein therapeutic for acute ischemic stroke. Closely comparable to DM199 as a recombinant biologic protein in stroke with similar mechanism-of-action profile targeting vascular/neuroprotective pathways.
Broad incumbents
- Stryker: Large medical device company with leading mechanical thrombectomy portfolio (Trevo) for ischemic stroke. Represents the dominant non-pharmacologic alternative to DM199 in the stroke treatment landscape.
- Roche: Global pharmaceutical company that distributes Actilyse (alteplase) internationally for acute ischemic stroke treatment. Provides incumbent competitive reference and global commercialization benchmark for DM199's potential stroke launch.
- Medtronic: Diversified medical device leader with neurovascular portfolio including stroke treatment technologies acquired from Covidien. Represents a key strategic competitor and potential acquirer in the stroke space.
- Penumbra: Medical device company specializing in stroke thrombectomy systems (Indigo, Lightning). Comparable as an incumbent in the acute ischemic stroke treatment market where DM199 would compete.
- Biogen: Major biopharmaceutical company that markets Activase (alteplase), the standard thrombolytic for acute ischemic stroke. Provides incumbent competitive context for DM199 in the stroke treatment paradigm.
Emerging players
- Comanche Biopharma: Clinical-stage biotech developing siRNA therapy (CMP-CPS-001) for preeclampsia. Direct emerging competitor to DiaMedica's preeclampsia program targeting the same orphan indication with no approved therapies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
DiaMedica social profiles
Digital presenceDiaMedica financial estimates
Financial estimateRevenue estimate
Valuation estimate
DiaMedica leadership team
Management profileNumber of profiles
Profiles9 records
DiaMedica funding detail
Funding detailFunding overview
Funding rounds14 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DiaMedica M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DiaMedica
What does DiaMedica do?
DiaMedica is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1), as a novel therapeutic for three ischemic/vascular indications: preeclampsia (Phase 2), fetal growth restriction (Phase 2), and acute ischemic stroke via the Phase 2/3 ReMEDy2 trial. The drug acts through the kallikrein-kinin system to restore vascular health, reduce inflammation and oxidative stress, and is currently advancing in clinical trials with no approved products or product revenue.
Is DiaMedica a public or private company?
DiaMedica is a public company. It is classified as public and is currently operating.
When was DiaMedica founded?
DiaMedica was founded in 2000. It employs 11 to 50 people.
Where is DiaMedica based?
DiaMedica is headquartered in Minneapolis, United States, in the North America region.
How does DiaMedica make money?
One revenue line is on record: drug Development / Licensing Revenue.
Who are DiaMedica's main competitors?
Direct peers on record are NoNO Inc., Athersys, ReNeuron Group and ZZ Biotech. Broad incumbents are Stryker, Roche, Medtronic, Penumbra and Biogen. Comanche Biopharma is listed as an emerging player.
Does DiaMedica have an API?
No public API is recorded for DiaMedica.
What industry is DiaMedica in?
DiaMedica's product category is Clinical-Stage Biopharmaceuticals (Ischemic/Vascular Therapeutics). Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.